Over 1050 New Jersey Auctions End Today - Bid Now
Over 20 Total Lots Up For Auction at One Location - TX Cleansweep 06/25

New study highlights effectiveness of iCAD's Xoft Electronic Brachytherapy System for early-stage breast cancer

Press releases may be edited for formatting or style | October 02, 2018 Rad Oncology Radiation Therapy Women's Health
NASHUA, N.H., (October 1, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of a long-term, independent study conducted with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT). With a mean follow-up of 55 months, outcomes published in The American Journal of Surgery showed that breast cancer recurrence rates of patients who were treated with IORT using the Xoft System and complied with adjuvant medical therapy were comparable to those seen in the cornerstone TARGIT-A study, which evaluated IORT using different technology. To date, this study presents the most long-term research of IORT using the Xoft System published in a peer-reviewed journal.

The retrospective study, Application of 21-gene recurrence scoreresults and ASTRO suitability criteria in breast cancer patients treated withintraoperative radiation therapy (IORT), evaluated the American Society for Radiation Oncology (ASTRO) suitability criteria for APBI and the 21-gene recurrence score for prognostic and predictive benefit in IORT patients over a nearly five-year period. The research was led by Barbara Schwartzberg, MD, FACS, conducted at the Rose Medical Center in Denver, Colo., and was not company sponsored.

"As the growing body of clinical evidence supporting the use of the Xoft System for IORT continues to mature and expand, we are thrilled to see members of our global base of clinical users publishing landmark results that validate the long-term effectiveness of our unique technology," said Ken Ferry, CEO of iCAD. "The compelling findings, comparable to other IORT methods previously examined, show IORT with the Xoft System is successful in delivering positive outcomes for patients with early-stage breast cancer that comply with their full course of treatment."

The study reviewed results of 184 patients with breast cancer from November 2011 to January 2016 completing Institutional Review Board (IRB)-approved IORT protocol. Data included demographics, histopathology, the 21-gene recurrence score, adjuvant therapy, locoregional and distant recurrences, and breast cancer-specific survival. All patients were classified by ASTRO suitability criteria (suitable: 64 percent, cautionary: 30 percent, unsuitable: 6 percent), with a mean follow-up of 55 months.

You Must Be Logged In To Post A Comment